Company intelligence / Profile preview

Engitix Therapeutics

London, England, United Kingdomengitix.com ↗
Ownership
Private
Employees
~50
Development stage
Preclinical
01

Overview

Engitix has developed a proprietary human ECM-based drug discovery platform that enables identification of novel therapeutic targets for fibrosis and solid tumors. The company has several preclinical programs targeting both intracellular and extracellular mechanisms driving these diseases. Its most advanced internal candidates are expected to enter clinical trials around or after 2025. The company also has major partnered programs with Takeda in liver fibrosis/NASH/IBD and with Dompé Farmaceutici in liver-associated cancers/fibrosis.

Therapeutic areas
GastroenterologyOncology
Modalities
Small moleculesAntibodiesOther biologics (based on ECM platform outputs)
Industry
Biotech
02

Drug pipeline

4 assets

EGTX004

Preclinical

3 more assets in the full pipeline.

Request access →
03

Partnerships

Takeda Pharmaceuticals — multi-program collaborations/licensing for liver fibrosis, NASH/MASH, IBD worth over $500 million+ biodollarsDompé Farmaceutici — strategic R&D collaboration/investment for precision medicines against fibrosis/liver cancer using AI-driven Exscalate platformMorphic Therapeutics — partnership for ECM-related target ID in IBD

Beyond the preview

Go deeper on Engitix Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Engitix Therapeutics.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call